Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 7/20 | 0.50 |
| ▸ | DPP4 | P27487 | 1/20 | 0.44 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.44 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.44 |
| ▸ | PREP | P48147 | 1/20 | 0.43 |
| ▸ | FAP | Q12884 | 1/20 | 0.43 |
| ▸ | XIAP | P98170 | 2/20 | 0.41 |
| ▸ | BIRC2 | Q13490 | 5/20 | 0.40 |
| ▸ | BIRC3 | Q13489 | 1/20 | 0.40 |
| ▸ | STAT6 | P42226 | 2/20 | 0.40 |
| ▸ | CASP1 | P29466 | 2/20 | 0.40 |
| ▸ | CASP4 | P49662 | 1/20 | 0.40 |
| ▸ | CASP5 | P51878 | 1/20 | 0.40 |
| ▸ | CASP7 | P55210 | 1/20 | 0.40 |
| ▸ | CASP9 | P55211 | 1/20 | 0.40 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.40 |
| ▸ | CASP10 | Q92851 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5992865 | 0.89 | ELANE (0.45) | ELANEDPP4DPP8DPP9PREP | |
| SCHEMBL13014699 | 0.87 | ELANE (0.51) | ELANEXIAP | |
| SCHEMBL10299168 | 0.87 | ELANE (0.51) | ELANEXIAP | |
| SCHEMBL3726967 | 0.85 | DPP4 (0.42) | ELANEDPP4DPP8DPP9PREP | |
| SCHEMBL11440574 | 0.83 | PREP (0.61) | DPP4DPP8DPP9PREPFAP | |
| SCHEMBL13014718 | 0.83 | ELANE (0.48) | ELANEXIAPBIRC2BIRC3 | |
| SCHEMBL20707055 | 0.80 | DPP4 (0.45) | ELANEDPP4DPP8DPP9PREP | |
| SCHEMBL13014809 | 0.80 | DPP4 (0.45) | ELANEDPP4DPP8DPP9PREP | |
| SCHEMBL15765626 | 0.80 | DPP4 (0.45) | ELANEDPP4DPP8DPP9PREP | |
| SCHEMBL13124665 | 0.79 | ACE (0.46) | XIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9278922-B2 | Anti-viral compounds | ABBVIE INC. (US) | 2016-03-08 | — | — | US | disclosed |
| US-20100317568-A1 | Anti-Viral Compounds | Abbott Labaoratories (US) | 2010-12-16 | — | — | US | disclosed |
| US-20100267634-A1 | Anti-Viral Compounds | Abbott Labaoratories (US) | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317568-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | ELANE 986/4885DPP4 159/4885DPP8 295/4885 |
| US-20100267634-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | ELANE 986/4885DPP4 159/4885DPP8 295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.